European Journal of Nuclear Medicine and Molecular Imaging

Papers
(The H4-Index of European Journal of Nuclear Medicine and Molecular Imaging is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
“Fuzzy” radiomics: the way forward for nuclear medicine imaging applications?289
EANM Springer Prizes 2020 awarded at EANM 2021198
Towards molecular imaging-guided intervention theatres in oncology181
Correction to: Preclinical SPECT and PET: Joint EANM and ESMI procedure guideline for implementing an efficient quality control programme171
Tumor agnostic ultrasmall nanoprobes for fluorescence-guided surgical resection in peritoneal metastasis170
Intriguing information from recent letter and article regarding unwanted targeting of salivary glands by PSMA ligands153
Robust and generalizable artificial intelligence for multi-organ segmentation in ultra-low-dose total-body PET imaging: a multi-center and cross-tracer study148
Prospective pilot study with [89Zr]Zr-girentuximab PET/CT: CA-IX imaging in metastatic triple negative breast cancer (OPALESCENCE)131
Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617107
Deep learning–based whole-body characterization of prostate cancer lesions on [68Ga]Ga-PSMA-11 PET/CT in patients with post-prostatectomy recurrence104
Melanin-targeted [18F]-PFPN PET imaging may shed light for clear cell sarcoma103
Highlights of the 34th EANM Annual Congress 2021, 2nd virtual edition: “FROM HAMBURG WITH LOVE”97
Vancomycin-based tracers guiding in situ visualization of bacteria on osteosynthesis devices and surgical debridement91
Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus88
Prospective clinical study of sentinel node detection in bladder cancer using a hybrid tracer – Towards replacement of pelvic lymph node dissection in cases with sentinel node visualization on SPECT/C88
Enhancing interpretability of AI with radiomics-based deep neural network: proof of concept in the classification of Parkinsonian syndromes with 18F-FDG PET imaging87
Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: A systematic review81
Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangli78
Assessment of [18F]PI-2620 Tau-PET Quantification via Non-Invasive Automatized Image Derived Input Function76
Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer70
Seasonal variation in D2/3 dopamine receptor availability in the human brain69
Combination therapy of an 211At-labeled RGD peptide and immune checkpoint blockade to enhance antitumor efficacy69
[18F]Fluorocholine PET/MRI and [18F]Fluorocholine PET/CT as first- and second-line imaging in primary hyperparathyroidism – who takes the lead?68
[68Ga]Ga-FAPI versus [18F]FDG PET/CT in the evaluation of Langerhans cell histiocytosis68
First-in-human imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 267
New horizons for the World Federation of Nuclear Medicine and Biology: achievements, partnerships, and future directions66
Low-dose dobutamine stress gated blood pool SPECT assessment of left ventricular contractile reserve in ischemic cardiomyopathy: a feasibility study62
Brain perfusion estimation by Tikhonov model-free deconvolution in a long axial field of view PET/CT scanner exploring five different PET tracers61
Real-time diagnosis of sampled lesions in targeted biopsy of prostate Cancer using a novel tracer [64Cu] Cu-DOTA-PSMA-3Q: a pilot preclinical study61
Dynamic frame-by-frame motion correction for 18F-flurpiridaz PET-MPI using convolution neural network61
Preclinical development of [18F]TAAR1-2203 as a PET radioligand for imaging TAAR1 expression and receptor occupancy59
Avid 18F-FDG uptake of benign gastric-type intraductal papillary mucinous neoplasm of the pancreas59
Persistent lung and vascular inflammation in mild to moderate COVID-19 survivors detected by ¹⁸F-FDG PET/CT: A quantitative imaging study with implications for cardiovascular risk57
A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer57
Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis54
Long-term impact of myocardial inflammation on quantitative myocardial perfusion—a descriptive PET/MR myocarditis study53
The feasibility of quantitative assessment of dynamic 18F-fluorodeoxyglucose PET in Takayasu’s arteritis: a pilot study53
Cinematic rendering of [18F]FDG-PET/MR52
[18F]FDG PET/MR to assess disease extension and inflammation in children and young adults with primary ciliary dyskinesia51
PSMA expression and PSMA PET/CT imaging in metastatic soft tissue sarcoma patients, results of a prospective study50
68Ga-FAPI and 18F-FDG PET/CT for predicting pathologic response and progression-free survival in locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy50
FAPI PET/CT in infectious, inflammatory, and rheumatological diseases: “watch it like a hawk” or “one swallow does not make a summer”?50
Nuclear imaging and therapy in oncology in Poland in 2021–202249
FAPI PET for monitoring of rheumatological treatment in multifocal peritoneal nodular fibrosis: a case study49
Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial48
Individual-level metabolic connectivity from dynamic [18F]FDG PET reveals glioma-induced impairments in brain architecture and offers novel insights beyond the SUVR clinical standard48
[68 Ga]Ga-FAPI versus [18F]F-FDG in malignant melanoma: complementary or counterpoint?48
Non-invasive visualization of liver fibrosis with [68Ga]Ga-DOTA-FAPI-04 PET from preclinical insights to clinical translation48
0.045263051986694